{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T06:17:47Z","timestamp":1791699467982,"version":"4.3.4"},"reference-count":59,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Linear IgA bullous dermatosis (LABD) is a rare autoimmune blistering disease. The induction of LABD by medications is a critical issue, with previous studies highlighting the link between specific drugs and the onset of LABD. This study aims to assess the reported associations between LABD and numerous available medications using the FDA adverse event reporting system (FAERS).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The study encompassed FAERS reports spanning the years 2004\u20132024. Medical Dictionary for Regulatory Activities (MedDRA) was used to identify cases of LABD. The Reporting Odds Ratio, Proportional Reporting Ratio, Bayesian Confidence Propagation Neural Network, and Empirical Bayes Geometric Mean were calculated to assess the reported associations between available drugs and LABD. A significant statistical association was considered when a drug signal met the criteria of all four algorithms.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In the FAERS database analysis, we identified 1,394 adverse event (AE) reports associated with LABD. The gender distribution of reports was relatively balanced, with the highest proportion in the 66\u201385 age group. The United States had the highest number of reports. Vancomycin and Amoxicillin were the most frequently reported drugs, with 559 and 58 reports, respectively. Through disproportionality analysis, we identified 34 drugs significantly associated with AEs of LABD, including antibiotics, antifungal medications, analgesics, nonsteroidal anti-inflammatory drugs, cardiovascular medications, and calcium channel blockers, among which the antibiotic Vancomycin showed the highest association. These results emphasize the need for further clinical attention to the safety of specific medications.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This is the first real-world study using the FAERS database to investigate drug-induced LABD. LABD is closely associated with antibiotic medications. Close monitoring of patients is required when these medications are used clinically to promptly detect and manage potential AEs such as LABD.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2025.1521697","type":"journal-article","created":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T15:59:36Z","timestamp":1737647976000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Linear IgA bullous dermatosis secondary to drugs: a real-world pharmacovigilance study of the FDA adverse event reporting system"],"prefix":"10.3389","volume":"12","author":[{"given":"Yixuan","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanzhang","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingnan","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanshuo","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,23]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.clindermatol.2011.03.008","article-title":"Linear immunoglobulin a bullous dermatosis","volume":"30","author":"Fortuna","year":"2012","journal-title":"Clin Dermatol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s13023-019-1089-2","article-title":"Linear IgA bullous dermatosis in adults and children: a clinical and immunopathological study of 38 patients","volume":"14","author":"Genovese","year":"2019","journal-title":"Orphanet J Rare Dis"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/j.1365-2230.1989.tb01980.x","article-title":"HLA type in bullous pemphigoid, cicatricial pemphigoid and linear IgA disease","volume":"14","author":"Venning","year":"1989","journal-title":"Clin Exp Dermatol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1111\/j.1365-2133.1988.tb03197.x","article-title":"A clinicopathological study of mucosal involvement in linear IgA disease","volume":"119","author":"Kelly","year":"1988","journal-title":"Br J Dermatol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1001\/archderm.1988.01670080012007","article-title":"Vancomycin-induced linear IgA bullous dermatosis","volume":"124","author":"Baden","year":"1988","journal-title":"Arch Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/s0190-9622(96)90073-0","article-title":"Vancomycin-induced linear IgA bullous dermatosis (LABD)","volume":"34","author":"Whitworth","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1111\/j.1365-4362.1985.tb05853.x","article-title":"Linear IgA bullous dermatosis. An immunologically defined disease","volume":"24","author":"Wilson","year":"1985","journal-title":"Int J Dermatol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1001\/archderm.131.1.48","article-title":"Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions","volume":"131","author":"Bernard","year":"1995","journal-title":"Arch Dermatol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"466","DOI":"10.2340\/00015555-1990","article-title":"Linear IgA bullous dermatosis: a retrospective study of 23 patients in Denmark","volume":"95","author":"Lings","year":"2015","journal-title":"Acta Derm Venereol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1111\/j.1525-1470.2006.00279.x","article-title":"Linear IgA bullous disease of childhood: an experience from Kuwait","volume":"23","author":"Nanda","year":"2006","journal-title":"Pediatr Dermatol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1001\/archderm.131.8.957","article-title":"Incidence of autoimmune subepidermal blistering dermatoses in a region of Central Germany","volume":"131","author":"Zillikens","year":"1995","journal-title":"Arch Dermatol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1001\/jamadermatol.2020.4006","article-title":"Linear immunoglobulin-a bullous dermatosis","volume":"157","author":"Pagliarello","year":"2021","journal-title":"JAMA Dermatol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"508","DOI":"10.2340\/00015555-3154","article-title":"Drug-induced linear IgA bullous dermatosis: a case report and review of the literature","volume":"99","author":"Lammer","year":"2019","journal-title":"Acta Derm Venereol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jdcr.2024.07.021","article-title":"Drug-induced linear IgA bullous dermatosis with extensive mucosal involvement","volume":"52","author":"Starzyk","year":"2024","journal-title":"JAAD Case Rep"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1159\/000353584","article-title":"Linear IgA bullous disease presenting as toxic epidermal necrolysis: a case report and review of the literature","volume":"227","author":"Kakar","year":"2013","journal-title":"Dermatology"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/0738-081x(93)90161-5","article-title":"Drug-induced linear immunoglobulin a disease","volume":"11","author":"Collier","year":"1993","journal-title":"Clin Dermatol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1046\/j.1365-2133.2001.04492.x","article-title":"Vancomycin-induced linear IgA disease with autoantibodies to BP180 and LAD285","volume":"145","author":"Palmer","year":"2001","journal-title":"Br J Dermatol"},{"key":"ref18","first-page":"157","article-title":"Early diagnosis is key in vancomycin-induced linear IgA bullous dermatosis and Stevens-Johnson syndrome","volume":"104","author":"Jones","year":"2004","journal-title":"J Am Osteopath Assoc"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1111\/ced.13030","article-title":"Piperacillin-tazobactam-induced linear IgA bullous dermatosis presenting clinically as Stevens-Johnson syndrome\/toxic epidermal necrolysis overlap","volume":"42","author":"Adler","year":"2017","journal-title":"Clin Exp Dermatol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1111\/bjd.12488","article-title":"Linear IgA bullous dermatosis: comparison between the drug-induced and spontaneous forms","volume":"169","author":"Chanal","year":"2013","journal-title":"Br J Dermatol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1046\/j.1440-0960.2003.00011.x","article-title":"Phenytoin-induced linear IgA dermatosis mimicking toxic epidermal necrolysis","volume":"44","author":"Tran","year":"2003","journal-title":"Australas J Dermatol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1111\/j.1365-2230.2004.01649.x","article-title":"Vancomycin-induced linear IgA bullous disease presenting as toxic epidermal necrolysis","volume":"29","author":"Waldman","year":"2004","journal-title":"Clin Exp Dermatol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1210\/clinem\/dgae417","article-title":"Post-marketing safety concerns of Teprotumumab: a real-world pharmacovigilance assessment","volume":"110","author":"Huang","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"111509","DOI":"10.1016\/j.jclinane.2024.111509","article-title":"A pharmacovigilance study of FDA adverse events for sugammadex","volume":"97","author":"Mao","year":"2024","journal-title":"J Clin Anesth"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/s0022-0981(00)00169-6","article-title":"Surface composition and orientation interact to affect subtidal epibiota","volume":"248","author":"Glasby","year":"2000","journal-title":"J Exp Mar Biol Ecol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/ced.14835","article-title":"Vesiculobullous skin reactions induced by COVID-19 mRNA vaccine: report of four cases and review of the literature","volume":"47","author":"Coto-Segura","year":"2022","journal-title":"Clin Exp Dermatol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1111\/ced.15007","article-title":"Linear IgA bullous dermatosis following Oxford AstraZeneca COVID-19 vaccine","volume":"47","author":"Hali","year":"2022","journal-title":"Clin Exp Dermatol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.jdcr.2022.04.021","article-title":"Toxic epidermal necrolysis-like linear IgA bullous dermatosis after third Moderna COVID-19 vaccine in the setting of oral terbinafine","volume":"24","author":"Han","year":"2022","journal-title":"JAAD Case Rep"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/cup.14305","article-title":"Eosinophil-rich linear IgA bullous dermatosis induced by mRNA COVID-19 booster vaccine","volume":"50","author":"Nahm","year":"2023","journal-title":"J Cutan Pathol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1111\/j.1365-2133.2003.05647.x","article-title":"Linear IgA disease: the IgA and IgG response to dermal antigens demonstrates a chiefly IgA response to LAD285 and a dermal 180-kDa protein","volume":"149","author":"Allen","year":"2003","journal-title":"Br J Dermatol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3181\/00379727-149-38738","article-title":"Early development of adipose cell lipogenesis and glycerol utilization in Zucker obese rats","volume":"149","author":"Martin","year":"1975","journal-title":"Proc Soc Exp Biol Med"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1111\/j.1365-2133.1997.tb14955.x","article-title":"Drug-induced linear IgA disease: target antigens are heterogeneous","volume":"136","author":"Paul","year":"1997","journal-title":"Br J Dermatol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1159\/000246933","article-title":"Antigenic specificity of antibodies from patients with linear basement membrane deposition of IgA","volume":"189","author":"Zone","year":"1994","journal-title":"Dermatology"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1172\/jci117354","article-title":"Interleukin 10 induces B lymphocytes from IgA-deficient patients to secrete IgA","volume":"94","author":"Bri\u00e8re","year":"1994","journal-title":"J Clin Invest"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1159\/000018173","article-title":"Drug-induced linear IgA bullous dermatosis associated with ceftriaxone- and metronidazole-specific T cells","volume":"199","author":"Yawalkar","year":"1999","journal-title":"Dermatology"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"588","DOI":"10.5021\/ad.2018.30.5.588","article-title":"Piperacillin-Tazobactam-induced linear IgA bullous dermatosis supported by a T-cell activation assay","volume":"30","author":"Ho","year":"2018","journal-title":"Ann Dermatol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"823","DOI":"10.20452\/pamw.3160","article-title":"Cytotoxic-based assays in delayed drug hypersensitivity reactions induced by antiepileptic drugs","volume":"125","author":"Por\u0119bski","year":"2015","journal-title":"Pol Arch Med Wewn"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13601-015-0073-8","article-title":"Pathogenesis and diagnosis of delayed-type drug hypersensitivity reactions, from bedside to bench and back","volume":"5","author":"Schrijvers","year":"2015","journal-title":"Clin Transl Allergy"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/s0190-9622(99)70414-7","article-title":"Drug-induced linear IgA bullous dermatosis probably induced by furosemide","volume":"41","author":"Cerottini","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"e38592","DOI":"10.7759\/cureus.38592","article-title":"Azithromycin as a possible cause of linear IgA bullous dermatosis","volume":"15","author":"O'Connell","year":"2023","journal-title":"Cureus"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"e49185","DOI":"10.7759\/cureus.49185","article-title":"Drug-induced linear IgA bullous dermatosis in an oncologic patient","volume":"15","author":"Quispe-G\u00e1rate","year":"2023","journal-title":"Cureus"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.jaad.2024.08.042","article-title":"Addressing vancomycin adverse cutaneous reactions","volume":"91","author":"Heymann","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"E40","DOI":"10.1111\/j.1525-1470.2007.00438.x","article-title":"Childhood linear IgA bullous disease triggered by amoxicillin-clavulanic acid","volume":"24","author":"Ho","year":"2007","journal-title":"Pediatr Dermatol"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1111\/j.1365-4632.2009.04104.x","article-title":"Amoxicillin-clavulanic acid-induced linear immunoglobulin a bullous dermatosis: case report and review of the literature","volume":"48","author":"Panasiti","year":"2009","journal-title":"Int J Dermatol"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1111\/j.1468-3083.2006.02066.x","article-title":"Amoxicillin-associated linear IgA bullous dermatosis","volume":"21","author":"Santos-Juanes","year":"2007","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"e13173","DOI":"10.1111\/dth.13173","article-title":"Linear IgA dermatosis of the childhood-report of an amoxicillin-induced case","volume":"33","author":"Stamenkovic","year":"2020","journal-title":"Dermatol Ther"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"e14187","DOI":"10.1111\/dth.14187","article-title":"Linear IgA bullous dermatosis: a rare manifestation of amoxicillin-clavulanic acid treatment","volume":"33","author":"Tabka","year":"2020","journal-title":"Dermatol Ther"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"e15232","DOI":"10.1111\/dth.15232","article-title":"Linear IgA bullous dermatosis secondary to piperacillin-tazobactam","volume":"35","author":"Garcia-Mouronte","year":"2022","journal-title":"Dermatol Ther"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"814","DOI":"10.5114\/ada.2023.133817","article-title":"Linear IgA dermatosis secondary to treatment with piperacillin-tazobactam in a nonagenarian patient","volume":"40","author":"Garc\u00eda-Paz","year":"2023","journal-title":"Postepy Dermatol Alergol"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/j.jaad.2011.09.018","article-title":"A critical reappraisal of the current data on drug-induced linear immunoglobulin a bullous dermatosis: a real and separate nosological entity?","volume":"66","author":"Fortuna","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1111\/j.1365-2230.2011.04297.x","article-title":"Amlodipine-induced linear IgA disease","volume":"37","author":"Low","year":"2012","journal-title":"Clin Exp Dermatol"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1046\/j.1365-4362.1998.00544.x","article-title":"Captopril-triggered linear IgA bullous dermatosis","volume":"37","author":"Friedman","year":"1998","journal-title":"Int J Dermatol"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/s0190-9622(94)70015-x","article-title":"Drug-induced linear IgA bullous dermatosis: report of six cases and review of the literature","volume":"30","author":"Kuechle","year":"1994","journal-title":"J Am Acad Dermatol"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/s0002-9343(02)01422-5","article-title":"Linear IgA bullous dermatosis induced by angiotensin receptor antagonists","volume":"114","author":"Pe\u00f1a-Penabad","year":"2003","journal-title":"Am J Med"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"230","DOI":"10.4103\/0378-6323.93663","article-title":"Linear IgA bullous dermatosis induced by ampicillin\/sulbactam","volume":"78","author":"Schafer","year":"2012","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jaad.2004.03.027","article-title":"Localized linear IgA disease induced by ampicillin\/sulbactam","volume":"51","author":"Shimanovich","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1111\/bjd.14069","article-title":"Causative drug detection by drug-induced lymphocyte stimulation test in drug-induced linear IgA bullous dermatosis","volume":"175","author":"Tomida","year":"2016","journal-title":"Br J Dermatol"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"995","DOI":"10.5070\/d329662995","article-title":"Linear IgA bullous dermatosis associated with immunotherapy","volume":"29","author":"Momin","year":"2023","journal-title":"Dermatol Online J"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1111\/ijd.15627","article-title":"Linear IgA\/IgG bullous dermatosis after nivolumab therapy","volume":"60","author":"Perandones-Gonz\u00e1lez","year":"2021","journal-title":"Int J Dermatol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1521697\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T15:59:39Z","timestamp":1737647979000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1521697\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,23]]},"references-count":59,"alternative-id":["10.3389\/fmed.2025.1521697"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1521697","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,23]]},"article-number":"1521697"}}